Kidney drug study: how avacopan behaves in dialysis patients

NCT ID NCT06468826

Completed Knowledge-focused Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 1 study looked at how the drug avacopan is processed in 13 people with normal kidney function and those with end-stage renal disease requiring hemodialysis. Researchers measured drug levels in the blood and dialysis fluid after a single dose. The goal was to understand safety and how the body handles the drug, not to treat the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: avacopan (oral capsules)
What this could lead to: If successful, this study could help doctors understand how to dose avacopan safely in kidney dialysis patients.
What could go wrong: This is a very early, small study (13 people) focused on drug levels, not treatment effects. Results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE (ESRD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

END STAGE RENAL DISEASE (ESRD)

Contacts and locations

Locations

Floridian Clinical Research, LLC

Miami Lakes, Florida, 33016, United States
Orlando Clinical Research Center

Orlando, Florida, 32809-3017, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.